Investigative studies exploring the synergy between DNMT inhibitors and ICIs point to the potential for enhanced anti-tumor immunity, which is critical for overcoming resistance and expanding the efficacy of immunotherapies (234). This evidence concerns the gene DNMT1 and neoplasm.